[Disclosure] Celltrion 068270 Signs KRW 712.5B Co-Development and License Agreement with Mustbio for Tri-specific Fusion Protein Therapeutics

Source Fact: Financial Supervisory Service DART / 2025-10-31

Disclosure Type: Major Management Matters Related to Investment Decisions

💡 3-Second Summary

Celltrion has partnered with Korean biotech Mustbio in a major licensing and joint development deal worth up to KRW 712.5B to co-develop a next-generation tri-specific fusion protein therapeutic targeting cancer.

📊 1. [Summary of Core Disclosure Content and Key Figures]

On October 31, 2025, Celltrion signed a joint research and development and licensing agreement with Mustbio Co., Ltd. for the development of ‘PD-1 x VEGF x IL-2v Tri-specific Fusion Protein’ novel drug candidates. Key metrics and transaction structures include:

• Scope of Agreement & Technology Transfer
  • The agreement leverages Mustbio’s proprietary cytokine and multi-antibody platforms to co-develop a novel tri-specific fusion protein and grants Celltrion licensing rights.
• Deal Value (Maximum KRW 712.5B)
  • Upfront Fee: KRW 3.0B (non-refundable fixed payment upon signing).
  • Development Milestones: Up to KRW 39.5B (payable step-by-step upon successfully achieving clinical stages from pre-clinical through regulatory approvals).
  • Commercialization Milestones: Up to KRW 670.0B (payable sequentially based on actual global net sales milestone achievements post-launch. The maximum payout of KRW 670.0B is triggered if cumulative net sales hit KRW 10.0T).
  • Royalties: 5% of net sales post-commercialization.
• Agreement Term
  • Commences on the contract date (October 31, 2025) and remains in effect until the later of: ① the expiration date of the relevant substance patents, or ② 10 years from the date of the first commercial sale.

📈 2. [Expert Insight: What This Disclosure Means for Investors]

• Expansion of Next-Generation Oncology Pipeline The target therapeutic ‘PD-1 x VEGF x IL-2v’ is a tri-specific agent designed to simultaneously inhibit immune checkpoints (PD-1), block angiogenesis (VEGF), and selectively activate immune cells (IL-2 variant). This move represents a vital step in Celltrion’s long-term fundamental transformation as it seeks to pivot from biosimilars into high-margin, original multi-targeting immuno-oncology pipelines.
• De-risked Financial Structuring Although the total deal value is reported at a substantial KRW 712.5B, the upfront cash requirement is limited to only KRW 3.0B. Given Celltrion’s massive annual revenues and solid cash flows, this upfront payment presents virtually zero immediate liquidity risk. The deal is effectively structured to share R&D risks with Mustbio.
• Inherent Risks of Milestone-based Agreements Investors should understand that over 99% of the contract value is highly conditional. Payments are entirely dependent on achieving specific R&D progress, clinical milestones, and massive commercial sales. If clinical outcomes fall short or regulatory authorities halt the program, the agreement can be terminated without any prior milestones being paid. Crucially, if the contract is terminated mid-way, Celltrion is not obligated to pay any termination penalties, making this a highly asymmetric, low-risk, high-reward bet.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion is playing the smart money game again! They’ve secured a highly promising tri-specific immuno-oncology asset valued at up to KRW 712.5B, while putting down an incredibly modest KRW 3B upfront. If the clinical trials run into a wall, Celltrion walks away cleanly with zero termination penalties. If it hits, they possess the keys to a massive global multi-targeting cancer block-buster. By blending checkpoint inhibition with cytokine activation, the technology represents the cutting edge of oncology. Using their strong biosimilar cash flows to purchase low-downside, high-upside lottery tickets is the ultimate playbook to transform into an original drug giant!

📢 Disclaimer & Source Information

Source: This content was structured and newly written based on the official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Advisory: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities remain solely with the investor.

Inquiries: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.